Clinical Analysis of Hypercoagulable Status and Hyperlipidemia in Children with Nephritic Syndrome Treated by Panax Notognsens

［Abstract］Objective　To observe the efficacy of Panax notognsens（PNS）combined with heparin in the treatment of hypercoagulable status and hperlipidemia in children with nephrotic syndrome．Methods　128 in-patient nephrotic syndrome children with hypercoagulable and hperlipidemia were selected and were treated with full Dosage Prednisonum［2 mg/(kg.d)，maximal dose 60 mg/d］and were randomly divided into 3 groups：heparin group［Prednisonum+heparin 125 u/(kg.d)，n＝42］，PNS group［Prednisonum+PNS 10 mg/(kg.d)，n＝43］and therapeutic alliance group［Prednisonum+heparin 125 μ/(kg.d)+PNS 10 mg/(kg.d)，n＝43］．The treatment lasted for 4 weeks．24 hours urine protein，blood Alb，Chol，TG，BUN，Scr and blood clotting function（PT， APTT，Fg，DD）were detected before and after 3 weeks of treatment．Results　The complete remission rate of therapeutic alliance group was 81.40%，which was significantly higher than that of heparin group and PNS group（P＜0.05）． 24 hours urine protein，blood Chol，TG and blood Fg，DD were significantly decreased and blood Alb was significantly increased after treatment than before（P＜0.05）．The changing of 24 hours urine protein and blood Alb of therapeutic alliance group was significantly different compared heparin group and PNS group（P＜0.05）．The blood Chol and TG of therapeutic alliance group and PNS group were significantly decreased than that of heparin group（P＜0.05）．The blood Fg and DD of therapeutic alliance group was significantly decreased than that of heparin group and PNS group（P＜0.05）．Conclusion　PHS combined with heparin has better effect in the treatment of children with nephritic syndrome complicating with hypercoagulable status and hyperlipidemia.